These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 21399946)
1. Prematurely ended phase III trials in Sweden during the years 2002-2008. Hedenmalm K; Johansson A; Bäckman K; Ohagen P Eur J Clin Pharmacol; 2011 Sep; 67(9):869-75. PubMed ID: 21399946 [TBL] [Abstract][Full Text] [Related]
2. Issues in data monitoring and interim analysis of trials. Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA; Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038 [TBL] [Abstract][Full Text] [Related]
3. Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials. Guinn D; Wilhelm EE; Shoulson I Ther Innov Regul Sci; 2020 Jan; 54(1):232-239. PubMed ID: 32008239 [TBL] [Abstract][Full Text] [Related]
4. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study. Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484 [TBL] [Abstract][Full Text] [Related]
5. Data monitoring committees, interim analysis and early termination in paediatric trials. Fernandes RM; van der Lee JH; Offringa M Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998 [TBL] [Abstract][Full Text] [Related]
6. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. Fernandes RM; van der Lee JH; Offringa M BMC Pediatr; 2009 Dec; 9():77. PubMed ID: 20003383 [TBL] [Abstract][Full Text] [Related]
7. On the independence of data monitoring committee in adaptive design clinical trials. Chow SC; Corey R; Lin M J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119 [TBL] [Abstract][Full Text] [Related]
8. Predictors of premature termination of cardiac surgery trials: insights from the Clinicaltrial.gov database. Cancelli G; Rossi CS; Dell'Aquila M; Mantaj P; Hirofuji A; Soletti G; Harik L; Cangut B; Al Zaghari T; Leith J; Falco G; Ibrahim M; Dimagli A; Rahouma M; Gaudino MFL Eur J Cardiothorac Surg; 2024 Aug; 66(2):. PubMed ID: 39133169 [TBL] [Abstract][Full Text] [Related]
9. Ethical preparedness of data monitoring committees (DMCs) to oversee international clinical trials: a qualitative descriptive study. Hinga A; Ibrahim A; Vintimilla D; Jones M; Eckstein L; Rid A; Shah SK; Kamuya D BMJ Glob Health; 2024 Aug; 9(8):. PubMed ID: 39182924 [TBL] [Abstract][Full Text] [Related]
10. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome. Zhao Y; Grambsch PM; Neaton JD Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513 [TBL] [Abstract][Full Text] [Related]
11. Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands. van den Bogert CA; Souverein PC; Brekelmans CTM; Janssen SWJ; Koëter GH; Leufkens HGM; Bouter LM J Clin Epidemiol; 2017 Aug; 88():140-147. PubMed ID: 28487159 [TBL] [Abstract][Full Text] [Related]
12. Should data monitoring committees assess efficacy when considering safety in trials in acute stroke? Bath PM; Gray LJ; Wahlgren NG Int J Clin Pract; 2007 Oct; 61(10):1749-55. PubMed ID: 17877661 [TBL] [Abstract][Full Text] [Related]
13. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941 [TBL] [Abstract][Full Text] [Related]
14. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent. Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413 [TBL] [Abstract][Full Text] [Related]
15. Trial watch: phase II and phase III attrition rates 2011-2012. Arrowsmith J; Miller P Nat Rev Drug Discov; 2013 Aug; 12(8):569. PubMed ID: 23903212 [No Abstract] [Full Text] [Related]
16. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Sydes MR; Altman DG; Babiker AB; Parmar MK; Spiegelhalter DJ; Clin Trials; 2004 Feb; 1(1):48-59. PubMed ID: 16281462 [TBL] [Abstract][Full Text] [Related]
17. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Adis International Ltd Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590 [TBL] [Abstract][Full Text] [Related]
18. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications. Alturki R; Schandelmaier S; Olu KK; von Niederhäusern B; Agarwal A; Frei R; Bhatnagar N; Hooft L; von Elm E; Briel M J Clin Epidemiol; 2017 Jan; 81():56-63. PubMed ID: 27614277 [TBL] [Abstract][Full Text] [Related]
19. A joint industry-sponsored data monitoring committee model for observational, retrospective drug safety studies in the real-world setting. Major-Pedersen A; McCullen MK; Sabol ME; Adetunji O; Massaro J; Neugut AI; Sosa JA; Hollenberg AN Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):9-16. PubMed ID: 33179845 [TBL] [Abstract][Full Text] [Related]
20. Premature termination of clinical trials in Spain: reasons, characteristics, and opportunities to improve. Filippi-Arriaga F; Boy RJ; Del Gobbo AD; Gallego AR Eur J Clin Pharmacol; 2023 Feb; 79(2):249-256. PubMed ID: 36525040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]